<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
OCTOBER 9, 2000
-----------------------------------------------------------
Date of Report (Date of earliest event reported)
INHALE THERAPEUTIC SYSTEMS, INC.
-----------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 023556 94-3134940
-------------------------------- ------------- -------------------------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
150 Industrial Road
SAN CARLOS, CA 94070
------------------------------------------
(Address of principal executive offices)
(650) 631-3100
----------------------------------------------------
(Registrant's telephone number, including area code)
----------------------------------------------------
(Former name, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS
On October 9, 2000, Inhale Therapeutic Systems, Inc. announced its
intention to issue $150 million aggregate principal amount of convertible
subordinated notes ($172.5 million if an over-allotment option is exercised in
full). A press release relating to the issuance is attached hereto as Exhibit
99.1.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits
99.1 Press Release dated October 9, 2000
.
2.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INHALE THERAPEUTIC SYSTEMS, INC.
Dated: October 9, 2000 By: /s/ Brigid A. Makes
------------------------------------------
Brigid A. Makes,
Chief Financial Officer and
Vice President, Finance and Administration
3.
